These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11796349)

  • 1. Oxidative modifications of kynostatin-272, a potent human immunodeficiency virus type 1 protease inhibitor: potential mechanism for altered activity in monocytes/macrophages.
    Davis DA; Read-Connole E; Pearson K; Fales HM; Newcomb FM; Moskovitz J; Yarchoan R
    Antimicrob Agents Chemother; 2002 Feb; 46(2):402-8. PubMed ID: 11796349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.
    Perno CF; Newcomb FM; Davis DA; Aquaro S; Humphrey RW; Caliò R; Yarchoan R
    J Infect Dis; 1998 Aug; 178(2):413-22. PubMed ID: 9697721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine.
    Baldwin ET; Bhat TN; Gulnik S; Liu B; Topol IA; Kiso Y; Mimoto T; Mitsuya H; Erickson JW
    Structure; 1995 Jun; 3(6):581-90. PubMed ID: 8590019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes.
    Kiriyama A; Nishiura T; Yamaji H; Takada K
    Antimicrob Agents Chemother; 1999 Mar; 43(3):549-56. PubMed ID: 10049266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.
    Kageyama S; Mimoto T; Murakawa Y; Nomizu M; Ford H; Shirasaka T; Gulnik S; Erickson J; Takada K; Hayashi H
    Antimicrob Agents Chemother; 1993 Apr; 37(4):810-7. PubMed ID: 8494379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere.
    Kiso Y
    Biopolymers; 1996; 40(2):235-44. PubMed ID: 8785365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Kynostatin (KNI)-272--a rationally designed tripeptide inhibitor of HIV protease].
    Kiso Y
    Nihon Rinsho; 1993 Sep; 51 Suppl():139-45. PubMed ID: 8271377
    [No Abstract]   [Full Text] [Related]  

  • 8. Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine.
    Mimoto T; Imai J; Kisanuki S; Enomoto H; Hattori N; Akaji K; Kiso Y
    Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2251-3. PubMed ID: 1423795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.
    Velazquez-Campoy A; Kiso Y; Freire E
    Arch Biochem Biophys; 2001 Jun; 390(2):169-75. PubMed ID: 11396919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
    Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease.
    Kar P; Lipowsky R; Knecht V
    J Phys Chem B; 2013 May; 117(19):5793-805. PubMed ID: 23614718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272.
    Wang YX; Freedberg DI; Yamazaki T; Wingfield PT; Stahl SJ; Kaufman JD; Kiso Y; Torchia DA
    Biochemistry; 1996 Aug; 35(31):9945-50. PubMed ID: 8756455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 protease does not play a critical role in the early stages of HIV-1 infection.
    Uchida H; Maeda Y; Mitsuya H
    Antiviral Res; 1997 Nov; 36(2):107-13. PubMed ID: 9443667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kynostatin and 17beta-estradiol prevent the apoptotic death of human neuroblastoma cells exposed to HIV-1 protease.
    Hawkins V; Shen Q; Chiueh CC
    J Biomed Sci; 1999; 6(6):433-8. PubMed ID: 10545779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages.
    Perno CF; Bergamini A; Pesce CD; Milanese G; Capozzi M; Aquaro S; Thaisrivongs S; Tarpley WG; Zon G; D'Agostini C
    J Infect Dis; 1993 Nov; 168(5):1148-56. PubMed ID: 8228348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology.
    Humphrey RW; Ohagen A; Davis DA; Fukazawa T; Hayashi H; Höglund S; Mitsuya H; Yarchoan R
    Antimicrob Agents Chemother; 1997 May; 41(5):1017-23. PubMed ID: 9145862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targets of a protease inhibitor, KNI-272, in HIV-1-infected cells.
    Goto T; Nakano T; Kohno T; Morimatsu S; Morita C; Hong W; Kiso Y; Nakai M; Sano K
    J Med Virol; 2001 Mar; 63(3):203-9. PubMed ID: 11170058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography.
    Adachi M; Ohhara T; Kurihara K; Tamada T; Honjo E; Okazaki N; Arai S; Shoyama Y; Kimura K; Matsumura H; Sugiyama S; Adachi H; Takano K; Mori Y; Hidaka K; Kimura T; Hayashi Y; Kiso Y; Kuroki R
    Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4641-6. PubMed ID: 19273847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI.
    Chokekijchai S; Shirasaka T; Weinstein JN; Mitsuya H
    Antiviral Res; 1995 Sep; 28(1):25-38. PubMed ID: 8585758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions.
    Davis DA; Yusa K; Gillim LA; Newcomb FM; Mitsuya H; Yarchoan R
    J Virol; 1999 Feb; 73(2):1156-64. PubMed ID: 9882317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.